标准剂量BEACOPP方案治疗晚期霍奇金淋巴瘤的疗效观察

摘要

目的 观察标准剂量BEACOPP方案治疗Ⅲ～Ⅳ期霍奇金淋巴瘤(HL)的疗效和安全性.方法 20例初治的晚期霍奇金淋巴瘤患者,均接受标准剂量BEACOPP方案化疗,初治肿瘤最大径≥5 cm或在化疗后有肿瘤病灶残留的患者给予局部放疗.结果 20例患者中14例完全缓解,4例部分缓解,总有效率为90％.主要不良反应为骨髓抑制和肝功能损害,其中2例患者出现Ⅱ度药物性肺损伤,治疗期间未发现治疗相关性死亡.结论 标准剂量BEACOPP方案治疗晚期霍奇金淋巴瘤安全有效.%Objective To observe the efficacy of the baseline BEACOPP regimen in the treatment of advanced Hodgkin' s lymphoma (HL).Methods Form January 2009 to January 2011,20 previously untreated patients with stages Ⅲ-Ⅳ HL were treated with the modified baseline BEACOPP regimen.Each patient was scheduled to receive 6-8 cycles of BEACOPP with consolidation radiotherapy to bulky(≥ 5cm) or residual disease.Results 14 patients achieved a complete remission (CR) and 4 patients had partial remission (PR),the total effective rate was 90％.The main toxic effects were bone marrow depression and liver injury.2 patients had grade 2 druginduced lung injury.No treatment-related death was observed.Conclusion The baseline BEACOPP regimen is effective and safe for advanced HL.